NCT02496078 - A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection | Biotech Hunter

Enrollment

207

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

February 28, 2017

Conditions

Hepatitis C

Interventions

DRUG

Daclatasvir

Daclatasvir tablet 60mg

DRUG

Asunaprevir

Asunaprevir soft capsule 100 mg

Trial Locations (29)

47392

Local Institution, Busan

100015

Local Institution, Beijing

100034

Local Institution, Beijing

100039

Local Institution, Beijing

100050

Local Institution, Beijing

100054

Local Institution, Beijing

110002

Local Institution, Shenyang

110006

Local Institution, Shenyang

127015

Local Institution, Moscow

130021

Local Institution, Changchun

190103

Local Institution, Saint Petersburg

191167

Local Institution, Saint Petersburg

200025

Local Institution, Shanghai

200062

Local Institution, Shanghai

200083

Local Institution, Shanghai

210002

Local Institution, Nanjing

210003

Local Institution, Nanjing

210029

Local Institution, Nanjing

212000

Local Institution, Zhenjiang

266011

Local Institution, Qingdao

410008

Local Institution, Changsha

510060

Local Institution, Guangzhou

510515

Local Institution, Guangzhou

610041

Local Institution, Chengdu

710038

Local Institution, Xi’an

710061

Local Institution, Xi’an

050051

Local Institution, Shijiazhuang

07061

Local Institution, Seoul

08308

Local Institution, Seoul